#SMC #precisiononcology #precisonmedicine #gastriccancer #zolbetuximab #NHSScotland #AstellasPharma #advancedgastriccancer #gastrooesophagealjunctioncancer #adenocarcinomatumours #biomarkers #cancerbiology #phase3clinicaltrials #SPOTLIGHT #GLOW
zurl.co/7GCPi
zurl.co/7GCPi
Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment - PharmaTimes
Decision introduces zolbetuximab for eligible patients in NHS Scotland
pharmatimes.com
January 20, 2026 at 12:04 PM